Artelo Biosciences, Inc.
  • About
    • About Artelo
    • Management
    • Board of Directors
    • Scientific Advisors
    • Contact
  • Pipeline
    • Overview
    • ART27.13
    • ART26.12
    • ART12.11
  • Science
    • Overview
    • Publications
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Media
  • Menu Menu
  • Twitter
  • LinkedIn
  • Facebook

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Media
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Email Alerts
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Media
Nov 12, 2024 8:00am EST

Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 05, 2024 8:30am EST

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

Oct 09, 2024 9:00am EDT

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Sep 04, 2024 9:00am EDT

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024 8:00am EDT

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 15, 2024 8:30am EDT

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 03, 2024 9:00am EDT

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jul 02, 2024 9:00am EDT

Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

Jul 01, 2024 9:00am EDT

Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium

Jun 04, 2024 8:30am EDT

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 15
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 - Artelo Biosciences, Inc.     info@artelobio.com    |     Terms of Use    |     Privacy Policy
  • Twitter
  • LinkedIn
  • Facebook